SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union

2026-02-26 - 14:17

SK–IDT–Vaxxas consortium establishes strategic entry point for high-density microarray patch (HD-MAP) vaccines in Europe to improve vaccine performance and access. Parallel development of high-immunogenicity HD-MAP vaccines for seasonal and pandemic influenza threats. INCHEON, South Korea, Feb. 26, 2026 /PRNewswire/ — SK bioscience announced that, together with IDT Biologika (IDT) and Australian biotechnology company Vaxxas, it